Latest news, reports, and more from the RedChip Nation.
Discovering Tomorrow's Blue Chips Today
November 05, 2019     Contact    
Can-Fite (NYSE American: CANF) Initiates Compassionate Use Program for Treatment of Liver Cancer


Can-Fite BioPharma (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced it has initiated its compassionate use program for Namodenoson in the treatment of hepatocellular cancer (HCC), the most common form of liver cancer.


Why It Matters: CANF’s compassionate use program has enrolled and started treating patients. The compassionate use program, which enables liver cancer patients not enrolled in Can-Fite’s clinical study to be treated with Namodenoson, is being administered by Dr. Salomon Stemmer, the Principal Investigator of the Company’s prior Phase II liver cancer study, and Professor at the Institute of Oncology, Rabin Medical Center, Israel. CANF recently completed a successful End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA), in which the FDA agreed with the Company’s proposed pivotal Phase III trial design to support a New Drug Application (NDA) submission and approval of Namodenoson in the treatment of HCC.


Key Quote: We are grateful to Dr. Stemmer for leading this compassionate use program, making Namodenoson available to patients who have exhausted all other treatment options. Based on the encouraging results of our recent Phase II trial, in which Namodenoson demonstrated clinical benefits in patients with underlying CPB7 cirrhosis, Can-Fite is committed to providing Namodenoson to fulfill the unmet medical need in this population.” - Dr. Pnina Fishman, CEO


The Backstory: CANF’s lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. The Company’s liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. FDA. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.



Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a cash fee of $5,000 monthly for 6 months of RedChip investor awareness services and consulting services. RedChip Companies also owns 16,500 shares of CANF Rule 144 stock, acquired in August 2019.

Paringa Resources (NASDAQ: PNRL) Generates $5.7M in Coal Sales in September Quarter


Paringa Resources (NASDAQ: PNRL) generated $5.7 million in coal sales in the quarter ended September 31, 2019, on 136,000 tons of coal shipments, up from 26,000 tons in the June quarter.


Why It Matters: PNRL is off to a strong start at its Poplar Grove mine in western Kentucky and expects a further increase in sales during the December quarter as the operations continue to ramp up. Unit 1 at Poplar Grove achieved 85% of nameplate Mains productivity in the #1 West Main through the second half of September, while Unit 2 has successfully been relocated to the #1 South Main, away from the geological fault, which will allow the Unit to continue to ramp up production.


The Backstory: PNRL operates the low cost, high quality Poplar Grove Mine, part of the Buck Creek Complex located in the Illinois Coal Basin in western Kentucky. The Buck Creek Complex includes two fully permitted thermal coal mines: (1) the operating Poplar Grove Mine with production capacity ramping up to 2.8 Mtpa; and (2) the permitted Cypress Mine with planned production capacity of 3.8 Mtpa. Construction of the Poplar Grove Mine has been completed and production ramp-up is underway, with full production capacity targeted in late 2020. The Company also has plans to develop the Cypress Mine. Western Kentucky is one of the world's best mining jurisdictions due to its access to low cost power, utilities, transportation and non-union labor pool. Mining conditions at Poplar Grove are similar to those encountered in neighboring mines, which rank as some of the most productive room-and-pillar operations in the world.



Paringa Resources Limited (PNRL) is a client of RedChip Companies, Inc. PNRL agreed to pay RedChip Companies, Inc., a $10,000 monthly cash fee for RedChip investor awareness services.

Immuron (NASDAQ: IMRN) Receives AUD $0.53M R&D Tax Concession Refund


Immuron (NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, announced that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $0.53 million for eligible research and development expenditure incurred during the 2019 Financial Year.


Why It Matters: The refund reflects IMRN’s continual investment made in its research and development programs during the 2019 Financial Year to progress its pipeline programs as well as the continuous development of the Company’s existing Travelan / Protectyn programs.


Key Quote: “This cash refund mechanism provides a non-dilutive way to help with the financing of our in-house programs. Immuron has an ambitious program underway to further the development of our unique hyperimmune bovine colostrum technology directed against gut-specific pathogenic organisms. We are presently in the process of a clinical program to take the IMM-124E/Travelan active pharmaceutical ingredient (API) forward under the auspices of the FDA to demonstrate IMM-124 can specifically prevent travelers’ diarrhea. And we are looking to move our second clinical drug candidate IMM-529 forward in the clinic to treat patients with C. difficile infections (CDI). This second clinical program will entail the submission of an investigational new drug (IND) application with FDA in the early part of 2020, with the intention of focusing the drug’s development to specifically deal with recurrent CDI in patients treated with antibiotics.” – Dr. Gary Jacob, CEO


The Backstory: IMRN has a novel and safe technology platform with one commercial asset, Travelan®, generating revenue. IMRN’s lead clinical candidate, IMM-124E, is presently being developed as a drug to prevent Travelers’ Diarrhea, and its second clinical-stage asset, IMM-529, targets Clostridium difficile Infections (CDI), and is presently in a clinical trial in CDI patients. These products together with the Company’s other preclinical immunotherapy pipeline products currently under development targeting immune-related and infectious diseases are anticipated to meet pressing needs in the global immunotherapy market.




Immuron Ltd. (IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a $7,500 monthly cash fee for investor awareness services.

Cyclo Therapeutics (OTCQB: CTDH) Signs Agreement with Leading CRO to Conduct Alzheimer’s Trial


Cyclo Therapeutics (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, signed an agreement with Worldwide Clinical Trials (Worldwide), a leading Contract Research Organization (CRO), to conduct a clinical trial to evaluate safety and efficacy in Alzheimer’s Disease. The trial will evaluate Trappsol® Cyclo™ given by intravenous infusion.


Why It Matters: CTDH has previously reported encouraging data on safety and efficacy of the product based on an FDA-approved expanded access program in a single patient with late-onset Alzheimer’s Disease. Alzheimer’s Disease affects 5.7 million Americans. While a few symptomatic treatments are available, there are no approved disease modifying treatments.


Key Quote: “We are very excited to work with Worldwide, an industry leader, on this critical clinical program. Our work to advance an innovative approach to treat this devastating disease may lead to improvements in the lives of Alzheimer’s patients and their families. We are pleased to have Worldwide’s team of experts working closely with us as we begin our development pathway.” -N. Scott Fine, Chairman and CEO


The Backstory: CTDH and Worldwide are designing the trial protocol and expect to schedule a scientific advice meeting with the U.S. FDA in early 2020. Patient enrollment is expected to begin shortly thereafter.



Cyclo Therapeutics (OTCQB: CTDH) is a client of RedChip Companies, Inc. CTDH paid RedChip Companies, Inc. a fee of $30,000 per month for four months of RedChip investor awareness services and consulting services, beginning in August 2019.

Genetic Technologies (NASDAQ: GENE) Provides Shareholder Update on Recent Achievements and Upcoming Milestones


Genetic Technologies (NASDAQ: GENE), a diversified molecular diagnostics company, announced an update to shareholders on recent achievements and upcoming milestones.


Key Highlights:

  • Completed $4.5M rights offering
  • Regained compliance with NASDAQ listing requirements
  • Preparing to commence sales of new GeneType tests for breast and colorectal cancers
  • Tests for cardiovascular disease, Type 2 diabetes, prostate cancer, and melanoma continues to progress; tests expected to launch before end of 2020
  • Signed three-year collaboration agreement with The Translational Genomics Research Institute

The Backstory: GENE is a diversified molecular diagnostics company offering cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class.



Genetic Technologies (GENE) is a client of RedChip Companies, Inc. GENE agreed to pay RedChip Companies, Inc. a $7,500 monthly cash fee for six (6) months of RedChip investor awareness services.

 > (OTCQB: CIIX) Subsidiary CBD Biotech to Attend Industrial Cannabis Conferences in China (OTCQB: CIIX), an established financial news and investment portal and a leading industrial hemp retailer for the Chinese-speaking community, announced that its subsidiary CBD Biotech attended the "2019 China Industrial Cannabis Investment Seminar" on October 31, 2019 in Shanghai, China and will attend the "2019 China Industrial Cannabis CBD Industry International Conference" on November 23-24, 2019, in Haerbing, China.


Why It Matters: These conferences are attended by companies and executives in China who are active in the industrial hemp market, like CBD Biotech, or have plans to enter the market in the near future, foreign industrial hemp companies, and institutional investors, secondary market institutional investors, and other high net worth investors interested in the industry. CBD Biotech executives are providing information and education on its industrial hemp-infused skincare and cosmetic products and its hemp wine and discussing its strategic plans for future development with conference attendees. Slated to launch two new industrial hemp products soon, CBD Biotech will also feature its new products at these conferences. Although the industrial hemp skincare and cosmetics industry is still in the early stages of development in China, as a first mover in this market, CBD Biotech has already laid the foundation to capitalize on this growing industry. It is legal in China to add industrial hemp/CBD extract to cosmetics, creating potential market of nearly 1.4 billion people for hemp-infused/CBD skincare and cosmetics.


The Backstory: Founded in 1999, CIIX endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products.


Disclosure, Inc. (CIIX) is a client of RedChip Companies. CIIX pays RedChip a cash fee of $10,000 monthly for six (6) months of investor awareness services.

SinglePoint’s (OTCQB: SING) Direct Solar Subsidiary Signs MOU for Marketing Collaboration


Direct Solar of America, a subsidiary of SinglePoint (OTCQB: SING), signed an MOU with SchollyME to collaborate on marketing Direct Solar through the schools that SchollyME is currently working with. The collaboration will put Direct Solar into the high school programs as a partner with SchollyME. This marketing strategy has already seen major success in driving new business for both companies.


Why It Matters: SchollyME is based in California and is the fastest growing sports recruiting app for all 32 NCAA sports. This partnership will assist schools and their athletic programs through giving back a percentage of sales to help support and fund the local high school programs. Direct Solar and SchollyME are currently working to define which markets to launch and in what capacity to do so. Supporting the local communities and high school programs will be the driver for this successful partnership. Working with the school to establish a presence for education on solar and renewable energy and what it means for future generations of kids is elemental in building longevity for both companies.


Key Quote: “We have seen major success in working with local high schools. We are currently working with 47 schools throughout Dallas, Houston, Fort Worth, Austin and are seeing amazing returns. We had our largest sales day to date Thursday closing seven deals for approximately $250,000. This partnership will give us access to high schools across the nation.” – Pablo Diaz, CEO


The Backstory: Direct Solar America is America’s Solar Energy Brokerage with more than 3,500 home installations, which has enabled residential solar customers to shop for options in order to find the best option for the home. Like Rocket Mortgage or Lending Tree, Direct Solar representatives provide homeowners with a variety of financing and service providers; this has made the process of buying solar much easier for homeowners. Direct Solar is operational in eight states and continues to expand its residential solar footprint. Direct Solar Commercial serves customers that own and/or manage commercial properties. Along with Direct Solar Capital, an alternative energy financing solution, commercial projects have access to $50,000 to $3 million in funding for solar installations.



SinglePoint, Inc. (SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee for RedChip investor awareness services and consulting services

Quote of the Week
"Business is one part knowledge, one part luck. In Hebrew we use the phrase: “Men size lam, mazel-mzl-l, knowledge and luck."
-Phil Sassower, Phoenix Group
Lesson of the Week
Byron Roth, Chairman and CEO of ROTH Capital, provides five key insights for small-cap investors.
Read More
Latest Videos
Could Cyclo Therapeutics (OTCQB: CTDH) have a Treatment for Alzheimers?
Cyclo Therapeutics (OTCQB: CTDH) was authorized by the FDA to use Trappsol® Cyclo™ for a late-onset Alzheimer’s Disease (AD) patient under a Compassionate Use Program which began intravenous dosing in May 2018.
Watch Now
Interview with CEO of Only Traditional Lithium Development Project in US
Watch our exclusive interview with Keith Phillips, CEO of Piedmont Lithium (NASDAQ: PLL), who discusses the company's development of the only traditional lithium project in the US.
Watch Now
Can-Fite BioPharma: Clinical Stage Drug Development Company with Target Price of $9.00
Watch our exclusive interview with Dr. Pnina Fishman, CEO of Can-Fite BioPharma Ltd. (NYSE American: CANF), an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH.
Watch Now
Ethema Health: New Paradigm in Mental Health Treatment
Watch our exclusive interview with Ethema Health Corporation (OTCQB: GRST) Chairman and CEO Shawn Leon. Ethema Health operates in the behavioral healthcare space, specifically in the treatment of substance-use disorders.The company has developed a unique treatment model that has shown to be highly effective at treating opioid addiction.
Watch Now
SinglePoint Investor Webinar
An exclusive investor webinar with SinglePoint (OTCQB: SING) President Wil Ralston. SinglePoint is a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration.
Watch Now
CIIX Interview: High Growth Investment Opportunity Targeting Chinese-Speaking Communities
Watch our exclusive interview with (OTCQB: CIIX) Chairman and CEO Warren Wang. CIIX has built a sizable audience of Chinese-speaking consumers globally through its legacy financial news business. The company is now leveraging those relationships to jump start a hemp and CBD business. Sales in this new segment hit nearly $1 million in the most recent quarter, up more than 500% over the prior year. Overall, CIIX is now operating at an $8 million annual revenue run rate with growth forecast to accelerate in the near-term.
Watch Now
Esports Entertainment: First Publicly Traded Bet Exchange for Global Esports
Esports Entertainment Group (OTCQB: GMBL) is a licensed online-gambling company specializing in e-sports wagering and 18+ gaming. The Company offers bet-exchangestyle wagering on e-sports events through a licensed, regulated, and secured platform to the global e-sports audience, currently excluding the US and EU, but with 2018 US SCOTUS decision, the market in the US could open rapidly.
Watch Now
Interview with SPI Energy CFO Anthony Chan
Watch our exclusive interview with SPI Energy (NASDAQ: SPI) CFO Anthony Chan. SPI is an established green energy player with global operations in key markets in Australia, Europe, Japan, and the United States. It is leveraging its solar platform and industry expertise to make strategic investment opportunities in green industries with significant growth and earnings potential and/or industries than can benefit from green power.
Watch Now
Santa Fe Gold Webinar Replay
Watch the replay of our exclusive webinar with Santa Fe Gold (OTC: SFEG) Technical Advisor Dan Gorski. SFEG is a US-based mining and exploration enterprise with 148 mining claims comprising 42 potential mines of which Jim Crow Gold and Silver Mine is already in production.
Watch Now
Order Small Stocks, Big Money Today!
Dave Gentry is the author of Small Stocks, Big Money: Interviews With Microcap Superstars. Published by Wiley, this first-hand perspective on the fast world of microcap investing is now available for purchase.
MidSouth Week in Review
The Fed lowered interest rates for the third time this year, sending the S&P 500 and NASDAQ to new all-time highs.
Read More
Weekly Index Performance
Major indexes posted another week of gains as the S&P 500 and NASDAQ reached new all-time highs.
Read More
About RedChip
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Disclosure
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at and view RedChip’s Disclosures.
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.